Diabetic Nephropathy Models

Your Strategic Guide to Diabetic Nephropathy Model Selection

Rational Model Selection Aligned with Disease Pathophysiology

Covers T1D platforms (NOD for immune-driven pathology, STZ for rapid hyperglycemia screening) and T2D platforms (HFD+STZ for flexible induction, db/db for classical early-mid stage, KK-Ay for metabolic phenotype, and ZDF/T2DN for advanced functional endpoints with progressive renal decline).

Disease Stage Stratification and Optimal Dosing Timing

Outlines preventive versus therapeutic dosing designs matched to distinct disease windows, including early renoprotection (4-8 weeks), metabolic-renal dual endpoints (8-12 weeks), progressive disease modification (8-12+ weeks), and immune-driven DN (long-term), with recommended initiation times and treatment durations for each scenario.

Actionable Efficacy Data from a Classic STZ+HFD-Induced DN Model

Presents a representative case with longitudinal readouts: fasting blood glucose dynamics, urinary albumin-to-creatinine ratio (UACR), glomerular sclerosis grading, mesangial matrix expansion, capillary basement membrane thickening, and tubular epithelial degeneration with vacuolar changes, validating compound renoprotective effects.

Clear Decision Pathway for Accelerated Study Design

Provides a straightforward prioritization sequence linking specific study objectives (immune-renal interactions, rapid screening, early-mid T2D-DN, obesity-driven DN, or advanced disease modification) to the optimal model choice, minimizing trial-and-error in preclinical planning and enhancing translational relevance.

Integrated Analytical Platforms Supporting Robust Endpoints

Highlights Ace Therapeutics' comprehensive infrastructure, including physiological and functional assay platforms, histology and pathology analysis (H&E, PAS, Masson), advanced imaging technologies, and molecular biology platforms for mechanistic exploration and biomarker discovery.

Download the full case study to access detailed model characterization data, experimental schedules, and validated assay protocols. Accelerate your DN drug development with Ace Therapeutics' strategic preclinical platform.

You might be interested in...